The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
The test runs on the company's Solana instrument, which can process up to 12 patient samples in a 45-minute run.
The urine-based test combines massively parallel sequencing with proprietary error-reducing technology developed at Johns Hopkins.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.
At Wired, a science journalist discusses her decision not to undergo BRCA testing.
The Japan Times says regulations are needed to oversee human genome-editing research.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.